UPDATE: Canaccord Genuity Initiates Coverage on ImmunoGen Ahead of Phase 3 Data

By: via Benzinga
In a report published Wednesday, Canaccord Genuity analyst John Newman initiated coverage on ImmunoGen (NASDAQ: IMGN) with a Buy rating ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.